Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients

Ashrafi, Farzaneh; Salmasi, Mehrzad

doi:10.4103/jrms.jrms_463_17

Cited by 6 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,14,17,18 Daily injections are used as G-CSF has a half-life of a 3-4 h, which can be extended by conjugating G-CSF with polyethylene glycol (PEGylation). 19,20 However, immune responses against PEG have been demonstrated to enhance clearance of PEG-G-CSF in an antibody-dependent manner. 21 As multiple cycles of PEG-G-CSF treatment are common, long-term treatment could be rendered ineffective.…”

Section: Introductionmentioning

confidence: 99%

“…Neutropenia is typically treated as an emergency and, in a subset of patients, the risk of neutropenia may be prophylactically addressed with post‐HSCT subcutaneous injection of recombinant human G‐CSF (filgrastim) to facilitate recovery 6,14,17,18 . Daily injections are used as G‐CSF has a half‐life of a 3–4 h, which can be extended by conjugating G‐CSF with polyethylene glycol (PEGylation) 19,20 . However, immune responses against PEG have been demonstrated to enhance clearance of PEG‐G‐CSF in an antibody‐dependent manner 21 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immune‐responsive biodegradable scaffolds for enhancing neutrophil regeneration

Kerr

McBride

Johnson

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

Neutrophils are essential effector cells for mediating rapid host defense and their insufficiency arising from therapy‐induced side‐effects, termed neutropenia, can lead to immunodeficiency‐associated complications. In autologous hematopoietic stem cell transplantation (HSCT), neutropenia is a complication that limits therapeutic efficacy. Here, we report the development and in vivo evaluation of an injectable, biodegradable hyaluronic acid (HA)‐based scaffold, termed HA cryogel, with myeloid responsive degradation behavior. In mouse models of immune deficiency, we show that the infiltration of functional myeloid‐lineage cells, specifically neutrophils, is essential to mediate HA cryogel degradation. Post‐HSCT neutropenia in recipient mice delayed degradation of HA cryogels by up to 3 weeks. We harnessed the neutrophil‐responsive degradation to sustain the release of granulocyte colony stimulating factor (G‐CSF) from HA cryogels. Sustained release of G‐CSF from HA cryogels enhanced post‐HSCT neutrophil recovery, comparable to pegylated G‐CSF, which, in turn, accelerated cryogel degradation. HA cryogels are a potential approach for enhancing neutrophils and concurrently assessing immune recovery in neutropenic hosts.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immune‐responsive biodegradable scaffolds for enhancing neutrophil regeneration

Kerr

McBride

Johnson

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…As a result, serum concentrations are sustained throughout the duration of neutropenia. Peg GCSF can be used as single dose in comparison to GCSF, and guidelines re ning the use of peg GCSF for prevention of chemotherapy induced febrile neutropenia has been published [11,12]. In a previous study to compare peg GCSG and GCSF in order to prevent neutropenic fever during consolidation with HIDAC, it was concluded that GCSF compared to peg GCSF was found to be statistically signi cantly associated with increased risk of hospitalization [13].…”

Section: Introductionmentioning

confidence: 99%

Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC)

Ghosh

2024

Preprint

View full text Add to dashboard Cite

Background: Consolidation therapy with high dose cytarabine (HIDAC) for Acute Myeloid Leukemia (AML)is associated with significant neutropenia , resultant infections and associated morbidities. In this prospective study on de novo AML patients we attempted to compare efficacy of peg GCSF vs GCSF in ameliorating the duration and severity of neutropenia. Material and methods: Fifty eight cycles of HIDAC(1,3,5) from 20 patients were studied. Twenty four hours after the consolidation chemotherapy, patients were randomized to receive either once daily short-acting GCSF (5 µg/kg) or single dose of long acting peg GCSF(6mg/100 µg per kg). Results: The median duration of neutropenia and episodes of febrile neutropenia were 9.0 and 15 in the GCSF arm and 9.8 days and 17 in the peg GCSF arm, respectively (p >0.05).. Incidence of positive microbiological cultures and mean duration of hospital stay was similar in the two arms. Conclusion: The results of this study failed to show any difference in the incidence and duration of febrile neutropenia, incidence of infections and associated morbidities, with the use of GCSF compared to peg GCSF in patients of AML on HIDAC consolidation therapy.

show abstract

Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis

Zheng

Mei

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

Background PEGylated granulocyte colony-stimulating factor (G-CSF) is a safe alternative to G-CSF to improve chemotherapyinduced neutropenia (CIN). This superiority has resulted in its increased use by physicians; however, the superiority of PEGylated G-CSF for CIN in breast cancer has not been conclusively determined. Objectives To assess the superiority of PEGylated G-CSF for CIN in breast cancer in terms of effectiveness and safety via a systematic review and meta-analysis. Methods A literature search in PubMed, Embase, Cochrane Library, and Web of Science was performed for eligible studies published from database inception to December 2019. All studies comparing PEGylated G-CSF and G-CSF for CIN of breast cancer were reviewed. After literature selection, data extraction and quality assessment were performed by two reviewers independently. Meta-analysis was conducted using Revman, version 5.2. Results Nine randomized controlled trials were finally identified. The publication bias of these studies was acceptable. For the endpoint of effectiveness, analysis of the incidence/duration of grade ≥ 3 neutropenia, the duration of grade 4 neutropenia, the incidence of febrile neutropenia (FN), and the time to absolute neutrophil count recovery showed no advantage of PEGylated G-CSF over G-CSF for CIN of breast cancer (P > 0.05), with the premise of a sufficient dose of G-CSF according to the guidelines. No significant differences in grade 4 adverse events were observed between the groups (P = 0.29), and PEGylated G-CSF did not increase the incidence of skeletal and/or muscle pain compared with G-CSF (P = 0.32). Conclusion PEGylated G-CSF was as effective and safe as G-CSF to reduce CIN in breast cancer but did not show an obvious superiority. However, in clinical practice, PEGylated G-CSF has an obvious advantage in terms of convenience, which could improve patient's quality of life.

show abstract

Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients

Cited by 6 publications

References 10 publications

Immune‐responsive biodegradable scaffolds for enhancing neutrophil regeneration

Immune‐responsive biodegradable scaffolds for enhancing neutrophil regeneration

Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC)

Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis

Contact Info

Product

Resources

About